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Myosin-IIBThe Ca2+/calmodulin complex interacts with and regulates various enzymes and target proteins known as
calmodulin-binding proteins (CaMBPs). This group of proteins includesmolecularmotors such asmyosins. In this
study, we show that non-muscle myosin-IIB is overexpressed in the brains of diabetic rats. We isolated CaMBPs
from the brains of non-diabetic rats and rats with streptozotocin-induced diabetes and puriﬁed them by
immobilized-calmodulin afﬁnity chromatography. The proteins were eluted with EGTA and urea, separated by
SDS-PAGE, digested and submitted to peptidemass ﬁngerprinting analysis. Thirteen intense bandswere found in
both types of brains, two were found exclusively in non-diabetic brains and four were found exclusively in
diabetic brains. A large fraction of the eluted proteins contained putative IQ motifs or calmodulin-binding sites.
The results of the myosin-IIB afﬁnity chromatography elution, western blot and RT-PCR analyses suggest that
myosin-IIB protein and mRNA are expressed at high levels in diabetic brains. This is the ﬁrst study that has
demonstrated differential expression of CaMBPs in diabetic and non-diabetic brain tissue through a comparative
proteomic analysis, and it opens up a new approach to studying the relationship between the expression of
myosins in the brain, hyperglycemia and intracellular calcium regulation.erlândia, Instituto de Genética
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Diabetes mellitus is a common metabolic disorder characterized by
hyperglycemia that affects the central nervous system, causing altera-
tions in neurotransmission, electrophysiological abnormalities, struc-
tural changes andmoderate disturbances in learningandmemory [1–5].
Hyperglycemia causes an acute rise in cytosolic calcium concentrations
due to increased calcium inﬂux into cells. In certain cells, hyperglycemia
causes the release of intracellular calcium stores aswell. Hyperglycemia
has also been associated with decreased calcium efﬂux [6]. The
combination of increased calcium inﬂux and decreased calcium efﬂux
leads to a sustained elevation of the basal level of cytosolic calcium that
may adversely affect cell functions, including Ca2+-binding proteinssuch as calmodulin and its target proteins, which are capable of
decoding very small changes in the intracellular concentration of
calcium [7].
Calmodulin is an ubiquitous, highly conserved acidic Ca2+-binding
protein [8]. Binding of Ca2+ releases Mg2+ from calmodulin and causes
the protein to undergo a conformational change that increases its
binding afﬁnity for a number of target proteins. Because Ca2+ binds to
calmodulin, a small change in the level of cytosolic calcium leads to a
large change in the level of active proteins such as Ca2+/calmodulin-
binding proteins [9,10].
Calmodulin-binding proteins can be classiﬁed into three categories
based on their calcium ion dependence: Ca2+-dependent, Ca2+-
independent and Ca2+-inhibited [8,9]. Calmodulin binds to the target
proteins via an IQmotif in a Ca2+-independentmanner [11], as has been
observed for the light chains of different myosin classes [12].
Myosins constitute a large family of actin-based motor proteins
[13] that contains more than 18 classes and multiple members.
Myosin classes I, II, V, VI, and IX are clearly present in vertebrate
neurons. Isoforms ofmyosin-II are expressed inmost non-muscle cells
and exhibit differences in their biological properties, tissue distribu-
tion and intracellular localization, indicating that each isoform might
Fig. 1. Proﬁle of calmodulin-binding proteins from brains of diabetic and non-diabetic
rats. (S) brain supernatant; (E1) proteins eluted from the CaM-Sepharose-4B column
with 2 mM EGTA; (E2) proteins eluted from the CaM-Sepharose-4B column with 6 M
urea; (1–16) CaMBP bands from the brains of diabetic and non-diabetic rats excised for
PMF analysis; (rectangles) CaMBP band identiﬁed as non-muscle myosin heavy chain
IIB (2) and cytoplasmic actin (11).
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for growth cone motility and axon outgrowth [16]. Total or partial
ablation of myosin-IIB can lead to damage to the nervous system as a
result of a defect in migration [17]. Furthermore, a recent study
showed that myosin-IIB is a necessary component of hippocampus-
dependent memory formation and synaptic plasticity in the mature
nervous system [18].
In the present investigation, we identiﬁed calmodulin-binding
proteins in non-diabetic and diabetic rat brains and investigated the
expression of non-muscle myosin heavy chain IIB in diabetic rat
brains.
2. Material and methods
2.1. Animals
Male Wistar rats (180–220 g) were housed under standard condi-
tions (22±1 °C, humidity 60±5%, 12-h light/12-h dark cycle) with
food and water ad libitum. All procedures for the handling, use and
euthanasia of animals followed the resolutions proposed by the
Brazilian Society of Science in Laboratory Animals and by the Ethics
Committee in Animal Research of the Federal University of Uberlândia,
Brazil.
2.2. Induction of diabetes mellitus
Rats were starved for 24-h, anesthetized by intraperitoneal
injection of xylazine/ketamine (1:1 v/v), and injected with strepto-
zotocin (40 mg/kg body weight, 0.01 M citrate buffer, pH 4.5; Sigma-
Aldrich) via the penile vein (2 mL/kg). Fasting continued for 90 min
after the injection. Ten days after injection with streptozotocin, rats
with fasting blood glucose levels above 200 mg/dL were scored as
diabetic. Glycemic levels were monitored for the subsequent 10 days
with Biocheck Glucose Test Strips (Bioeasy). Animals were sacriﬁced
by decapitation 20 days after the induction of diabetes and brains
from both diabetic (n=16) and non-diabetic (n=16) rats were
surgically removed.
2.3. Afﬁnity chromatography
Calmodulin-coupled Sepharose-4B resin afﬁnity chromatography
(CaM-Sepharose-4B, Amersham Pharmacia Biotech) was carried out as
previously described [19]. The resin was loaded into a glass column
(10×0.5 cm) and equilibrated with 10 volumes of equilibration buffer
(50 mM Tris–HCl, pH 7.5, 2 mM CaCl2, 1 mM β-mercaptoethanol)
containing 100 mMNaCl. For each sample, four brains of the same type
were homogenized on ice in three volumes of homogenization buffer
(50 mMTris–HCl, pH 7.5, 1 mMEDTA, 1 mMβ-mercaptoethanol, 1 mM
benzamidine, 0.2 mM phenylmethane sulfonyl-ﬂuoride (PMSF),
0.1 mM aprotinin, 20 μg/mL leupeptin, 0.1 mM pefabloc). The homog-
enate was centrifuged at 15,000×g for 30 min at 4 °C. Supernatants
were prepared for CaM-Sepharose-4B afﬁnity chromatography by
adding 2 mM CaCl2. Following application to the column, the excluded
volume was discarded and the resin was washed with 10 volumes of
equilibration buffer containing200 mMNaCl, followedby10volumes of
the same buffer containing 500 mM NaCl. CaMBPs were eluted
with buffer containing 50 mM Tris–HCl (pH 7.5), 2 mM EGTA, 1 mM
β-mercaptoethanol, 100 mM NaCl and 0.2 mM PMSF, followed by
elution with buffer containing 50 mM Tris–HCl (pH 7.5), 6 M urea,
1 mM β-mercaptoethanol and 0.2 mM PMSF. Afﬁnity chromatography
was performed without speciﬁc protection of phosphate/phosphatases,
and puriﬁcation was carried out in triplicate. The protein content of the
loaded supernatants and eluted fractions was estimated following a
modiﬁcation of the Bradford assay [20] and samples with protein
concentrations below2 μg/μLwere treatedwith 10% trichloroacetic acid
for 15 min on ice, and centrifuged at 12,000×g for 10 min at 4 °C. Theprotein precipitate was then solubilized in a small volume of electro-
phoresis sample buffer containing an additional 100 mM Tris–HCl
(pH8.0) and 25% glycerol, analyzed on a 5–22% gradient SDS-PAGE [21],
and stained with Coomassie Brilliant Blue R-250.
2.4. Protein digestion and mass spectrometry
Prior to peptidemass ﬁngerprinting analysis (PMF), the calmodulin-
binding proteins of the eluted fractions were destained in the
polyacrylamide gel. Tryptic digests were prepared on an AnchorChip™
plate (Bruker Daltonics) according to the modiﬁed method of Zhang et
al. [22].Mass spectrawere obtainedusinganAutoﬂex IIMALDI-TOF/TOF
mass spectrometer (Bruker Daltonics) in delayed extraction and
reﬂector modes. The spectra were processed using the FlexAnalysis
2.4 and BioTools 3.0 software tools (Bruker Daltonics). Peptide masses
(MH+)were recorded in the range of 700–3500 Da. Internal calibration
was performed using known trypsin autolysis ion peaks (842.50 and
2211.09).
2.5. Database search
The monoisotopic masses of tryptic peptides were used to identify
the proteins by peptide mass ﬁngerprinting. Protein searches in the
National Center for Biotechnology Information (NCBI) database were
carried out using Mascot software [23], assuming a p-valueb0.05. The
error tolerance for peptide mass was lower than 100 ppm. No re-
strictions were imposed on protein molecular mass or phylogenetic
lineage. Searches that provided no signiﬁcant scores were then re-
stricted to Rodentia. Further search parameters were the presence
of one missed cleavage and the presence of sites for modiﬁcations,
including methionine oxidation, cysteine carbamidomethylation and
N-terminal acetylation (protein). Identiﬁed proteins were categorized
via UniProt/TrEMBL. Those proteins that could not be categorized
using this method were classiﬁed according to cellular localization
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web-based database (http://calcium.uhnes.utoronto.ca/ctdb) was
used to identify putative CaM-binding motifs within the primary
sequence of the identiﬁed proteins; these motifs were classiﬁed as
“potential IQ motif,” “potential motif 1–5–10 subclass,” “potential
CaM-binding site,” “nonspeciﬁc CaM-binding site” and “absent CaM-
binding motif” [10,24].2.6. Western blotting for myosin-IIB expression
Three diabetic and three non-diabetic brains (n=3, respectively)
were homogenized in homogenization buffer (50 mM Tris–HCl, pH 7.5,
10 mM EDTA, 2 mM EGTA, 5 mM ATP, 2 mM dithiothreitol, 1 mM
benzamidine, 0.5 mM phenylmethane sulfonyl-ﬂuoride, 0.1 M aproti-
nin, 20 μg/mL leupeptin, 0.1 mMpefabloc) and centrifuged at 15,000×g
for 30 min at 4 °C. The protein content of the supernatants was
estimated using the Bradford assay. Supernatant samples containing
30 μg of protein were solubilized in a small volume of electrophoresis
sample buffer containing an additional 100 mM Tris–HCl, pH 8.0, and
25% glycerol, analyzed by 5–22% SDS-PAGE and electroblotted on
nitrocellulose membranes in Tris–glycine buffer [25]. The membranes
were incubated with 5% dried milk in TBS-T (50 mM Tris–HCl, pH 8.0,
150 mM NaCl, 0.05% Tween 20) and then probed with 0.2 μg/mL anti-
myosin-IIB primary antibody. Following washes with TBS-T, the blots
were incubated with a peroxidase-conjugated anti-rabbit IgG (GE
Healthcare; diluted 1:2000) and againwashed several timeswith TBS-T.
Antibodies bound to the membranes were visualized by chemilumi-
nescence after treatment with ECL™ (GE Healthcare) followed byTable 1
Identiﬁcation of calmodulin-binding proteins in the brains of diabetic and non-diabetic rats
column 6 M urea; (MMt) theoretical molecular mass (in kDa) as assigned in the NCBInr datab
weight standards; (PIQM) potential IQ motif; (1–5–10 motif) potential motif of the 1–5–10
binding site; (NoM) calmodulin-binding motif absent.
Accession Protein name
D1 gi|148491097 Cytoplasmic dynein 1 heavy chain 1
D2* gi|13928704 Nonmuscle myosin heavy chain IIB
D3 gi|31543764 Alpha-spectrin 2
D4 gi|6978593 Calcium/calmodulin-dependent protein kinase II alph
D5 gi|62646604 Similar to ubiquitin protein ligase E3C
gi|57977273 Phosphofructokinase, platelet
D6 gi|149041705 Acyl-CoA synthetase bubblegum family member 1
D7 gi|13242237 Heat shock protein 8
D8 gi|125287 Calcium/calmodulin-dependent protein kinase II beta
D8* gi|149064377 Calcium/calmodulin-dependent protein kinase II alph
D9 gi|6978593 Calcium/calmodulin-dependent protein kinase II alph
D10* gi|7106439 Tubulin, beta 5
D11* gi|109492380 Similar to actin, cytoplasmic 2 gamma
D12 gi|224839 Tubulin T beta 15
D13 gi|8394006 Zinc ﬁnger protein 260
D14 gi|223556 Tubulin alpha
D15 gi|197313643 Glycolipid transfer protein
D16 gi|148667971 Tubulin, alpha 4
ND1 gi|109499266 Similar to centromere protein F
ND2 gi|209364564 Microtubule-actin crosslinking factor 1
ND3 gi|6978593 Calcium/calmodulin-dependent protein kinase II alph
ND4 gi|2646604 Similar to ubiquitin protein ligase E3C
ND5 gi|57977273 Phosphofructokinase, platelet
gi|149041705 Acyl-CoA synthetase bubblegum family member 1
ND6 gi|13252237 Heat shock protein 8
ND7 gi|125287 Calcium/calmodulin-dependent protein kinase II beta
ND8 gi|6978593 Calcium/calmodulin-dependent protein kinase II alph
ND8* gi|149064377 Calcium/calmodulin-dependent protein kinase II alph
ND9 gi|7106439 Tubulin, beta 5
ND10* gi|109492380 Similar to actin, cytoplasmic 2 gamma
D11 gi|224839 Tubulin T beta15
ND12 gi|148667971 Tubulin. alpha4
ND13 gi|223556 Tubulin alpha
ND14 gi|6959684 Glycolipid transfer protein
ND15 gi|148667971 Tubulin, alpha 4exposure to Hyperﬁlm™ (GE Healthcare) following manufacturer's
instructions. The intensity of the protein bands was analyzed and
compared using Scion Image software, version Alpha 4.0.3.2 (Scion
Corporation) and results were expressed as percentage of total protein
content.
2.7. RNA isolation and cDNA synthesis
Total RNA was isolated from four diabetic and four non-diabetic
brains using TRIzol reagent (Invitrogen) following the manufacturer's
instructions and then resuspended in DEPC-treated water. The quality
and quantity of the isolated RNA were established by reading the
optical density of each sample at 260 and 280 nm using NanoDrop®
ND-1000 Spectrophotometer (Nanodrop Technologies) and agarose
gel electrophoresis. One microgram of total RNA was reverse
transcribed at 37 °C for 1 h in a 20 μL reaction mixture containing
the ﬁrst strand buffer, 40 U Murine Monoley Leukemia Virus Reverse
Transcriptase (Invitrogen), 0.25 mM of each dNTP, 10 U RNAsin
(Invitrogen), 0.5 mM DTT, and 126 pmol hexamer random primers
(Invitrogen).
2.8. Preparation of quantiﬁcation standard
Standardswere prepared by cloning PCR products ofMYH10 and the
housekeeping gene beta-2-microglobulin (B2M) fragments using TOPO
TA Cloning Dual Promoter Kit (Invitrogen). The recombinant plasmid
DNA was isolated and sequenced using MegaBACE 1000 automatic
sequencer (Molecular Dynamics). The sequencing reaction was. (D) Diabetic; (ND) non-diabetic; (*) CaMBPs eluted from the CaM-Sepharose-4B with
ase; (MMe) experimental molecular mass (in kDa) based on the commercial molecular
subclass; (PCaMS) potential calmodulin-binding site; (UcM) nonspeciﬁc calmodulin-
MMt MMe Score Motif
534.45 N180 160 UcM at 3155 aa
229.79 N180 86 PCaMS
285.22 180–116 86 PCaMS
a 54.65 180–116 121 1–5–10 motif at 296
124.86 116 183 PIQM at 48 aa
86.63 90–58 176 PCaMS
69.77 115 PCaMS
71.05 58 61 UcM at 257 aa
61.10 48.5 220 1–5–10 motif at 297
a 54.84 48.5–36.5 64 1–5–10 motif at 298
a 54.65 139 1–5–10 motif at 296
50.09 48.5–36.5 75 PCaMS
59.16 48.5–36.5 84 NoM
50.36 36.5 83 PCaMS
48.09 26.6 70 PCaMS
50.89 N26.6 99 PCaMS
23.86 N26.6 62 PCaMS
28.13 N26.6 72 PCaMS
358.01 N180 72 PCaMS
623.21 180 62 PIQM at 2136 aa and 2549 aa
a 546.51 180–116 141 1–5–10 motif at 296
124.86 116 213 PIQM at 48 aa
86.63 90–58 103 PCaMS
69.7 90–58 155 PCaMS
69.77 90–58 155 UcM at 257 aa
61.10 48.5 130 1–5–10 motif at 297
a 54.65 84.5–36.5 100 1–5–10 motif at 296
a 54.84 48.5–36.5 1115 1–5–10 motif at 298
50.09 48.5–36.5 64 PCaMS
59.16 48.5–36.5 64 Nom
50.36 36.5 67 PCaMS
28.13 26.6 63 PCaMS
50.89 N26.6 103 PCaMS
23.87 N26.6 85 PCaMS
28.13 N26.6 117 PCaMS
46 L.K. Calábria et al. / Journal of the Neurological Sciences 303 (2011) 43–49carried out using the DyEnamic ET Dye Terminator Cycle Sequencing
Kit (GE Healthcare) following the manufacturer's instructions. The
plasmid concentration was measured and the copy numbers calculated
according to Yin et al. [26]. Serial dilutions of each standard were
made in the range of 10 to 107 copies per μL for MYH10 and B2M.
The efﬁciency reaction was calculated according to the formula
E=(10−1/slope−1)×100, where the log of each dilution was plotted
against ΔCT of the housekeeping and target genes.
2.9. Real-time PCR conditions
The qPCR assay was carried out in a 7300 Real-time PCR System
(PE Applied Biosystems) using SYBR Green qPCR Master Mix reagent
(Fermentas). Thermal cycling was conducted using the Universal
Program proﬁle (PE Applied Biosystems). Primers were designed
between exon junctions to avoid ampliﬁcation of contaminating
genomic DNA using Primers Express software (PE Applied Biosystems).
The primers used for B2M fragment ampliﬁcationwere 5′-CGT CGT GCT
TGC CAT TCA-3′ and 5′-TCC TCA ACT GCT ACG TGT CTC AG-3′. TheFig. 2.MALDI-TOF MS spectrum and properties of myosin-IIB. (A) Spectrum of the peptide m
and the intensity of the molecular ions (y-axis). From the results of the MS analysis, all peaks
of the main characteristics of the myosin-IIB identiﬁcation in the database. (C) Myosin-IIB seq
from the spectrum (underlined/bold).MYH10 forward and reverse primers were 5′-CCA TGC CGG AGA ACA
CAG T-3′ and 5′-AAG CCC AGA CCA AAG AGC AG-3′, respectively. The
relative expression of each speciﬁc product was calculated by 2−ΔΔCT
(CT=ﬂuorescence threshold value; ΔCT=CT of the target gene−CT
of the reference gene (B2M); ΔΔCT=ΔCT of the target sample−ΔCT
of the calibrator sample). All samples were run in duplicate.
2.10. Immunohistochemistry
Brains were dissected and ﬁxed with 10% formaldehyde solution in
0.1 M phosphate-buffered saline (pH 7.4) for 24 h, dehydrated in
ethanol, rinsed in xylene and embedded in parafﬁn. Five micrometer
sections were pretreated with 4 mM citrate buffer (pH 6.0) containing
0.025% Tween 20 in a microwave for 5 min. The sections were then
incubated with anti-myosin-IIB for 16 h followed by incubation with
the Post Primary Block NovoLink™ Max Polymer Detection System
(Novocastra Laboratories Ltd.). After three washes with TBS-T, the
sectionswere incubatedwith theNovoLink polymer for 30 min at 37 °C.
Chromogen development was performed with 3,3′-diaminobenzidine,asses generated from the digested band showing them/z (mass to charge ratio) (x-axis)
represent peptides used for identiﬁcation of the protein as myosin-IIB by PMF. (B) Table
uence (accession number 13928704) indicating the regions covered by the 61 peptides
Fig. 3.Myosin-IIB expression in non-diabetic and diabetic rat brains. Western blots and
quantiﬁcation of myosin-IIB expression from supernatant samples of non-diabetic and
diabetic rat brains. The amount of myosin-IIB protein presented on the immunoblot
was determined densitometrically and expressed as a related percentage of the non-
diabetic and diabetic groups. (*) pb0.05, n=3 rats/group.
Fig. 4. MYH10 expression in the non-diabetic and diabetic rat brains. (A) The box-plot
diagram shows signiﬁcantly upregulated MYH10 mRNA expression in the diabetic
compared to non-diabetic brain samples. (*) pb0.001, n=6 rats/group. (B) Standard
curves for Rattus norvegicus B2M (R2=0.9997, slope=−3.73) andMYH10 (R2=0.996,
slope=−3.27) generated by plotting the value of CT cycle vs. the log of plasmid
concentration (from 104 to 106 copies). Linear regression graphic was used to determine
the ampliﬁcation efﬁciency.
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dehydrated, mounted with Permount and analyzed using a light mi-
croscope (Zeiss Axiolab). Negative controls were prepared by omitting
the primary antibody from the reaction.
2.11. Statistical analysis
Statistical analysis was performedwith the Student t-test. The data
were analyzed using SigmaStat 3.5 software (Systat Software Inc.).
Means and standard deviations were calculated. A p-valueb0.05 was
considered signiﬁcant.
3. Results and discussion
In this study, we identiﬁed proteins from non-diabetic and diabetic
rat brains that interact with the Ca2+/calmodulin complex. SDS-PAGE
analysis of the EGTA-eluted fractions from a CaM-Sepharose-4B column
revealed a similar protein proﬁle for both types of brains, with ﬁfteen
intense bands for non-diabetic and sixteen for diabetic brains (Fig. 1).
The fraction eluted with 6 M urea revealed two proteins that were
highly expressed in diabetic brains, myosin-IIB and cytoplasmic actin.
Two calmodulin-binding proteins were found only in non-diabetic
brains, four were exclusively identiﬁed in diabetic and thirteen were
found in both types of rat brains (Table 1). The sequencesof all identiﬁed
proteins were analyzed for the presence of a calmodulin-binding motif
using the databasewith respect to the presence of a calmodulin-binding
motif. The proteins were classiﬁed as “potential IQ motif” (two),
“potentialmotif 1–5–10 subclass” (two), “potential calmodulin-binding
site” (eleven), “nonspeciﬁc calmodulin-binding motif” (two) and
“absent calmodulin-binding motif” (one), as shown in Table 1.
Two metabolic enzymes that are also well-known calmodulin-
binding proteins were identiﬁed, phosphofructokinase and acyl CoA
synthetase. Although phosphofructokinase was found in both types of
brains, it has been reported that the levels of this enzyme are
decreased in diabetic brains [27]. A number of cytoplasmic proteins
were also identiﬁed in both the non-diabetic and diabetic brains:
glycolipid transfer protein, a protein that accelerates the intermem-
brane transfer of various glycolipids [28]; ubiquitin protein ligase E3C,
which is thought to be the component of the ubiquitin conjugation
systemmost directly responsible for substrate recognition [29,30] and
modulating the function of the synapse [31]; and heat shock protein
8 (HSP70). Previous studies have shown that calmodulin binds to
HSP70 in a calcium-dependent manner [32] and activates calcineurin
via calmodulin-dependent and independent pathways [33]. Members
of the HSP70 family often act as chaperones, regulating the folding
and stability of several proteins, including receptors and signal
transduction regulators, or as biomarkers of cellular death [34].
Calmodulin is present in the nucleus of multiple cell types,
suggesting that it is involved in the regulation of nuclear functions
[9]. We detected three proteins predicted by Psort II to be localized to
the nucleus: zinc ﬁnger protein 260, similar centromere protein F and
microtubule-actin crosslinking factor 1. The identiﬁcation of nuclear
proteins was not unexpected because subcellular fractionation of
biological samples is seldom complete [35]. Furthermore, all of these
proteins interact with calmodulin and contain calmodulin-binding
motifs.
Both the alpha and beta isoforms of Ca2+/calmodulin-dependent
protein kinase II (CaMKII) were identiﬁed. These common neural
proteins mediate diverse physiological responses to increases in
intracellular calcium concentrations by Ca2+/calmodulin complex
activation in neurons [36]. The alpha and beta isoforms are neuron
speciﬁc and highly abundant in rat brains [37]. CaMKII seems to be
relatively vulnerable to pathological states that are associated with
massive calcium inﬂuxes into cells [38]. The activity and enzyme
content of CaMKII are increased in diabetic rat brains; this changemay
be a molecular cause of previously reported deﬁcits in learning and
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distinct bands of CaMKII that differed slightly in mass in both diabetic
and non-diabetic brains, suggesting that the protein exists in different
states of post-translational modiﬁcations such as phosphorylation,
which is a key factor in the trafﬁcking and functioning of this protein
[40].
Several of the identiﬁed proteins, including actin, dynein, myosin,
spectrin and tubulin, are implicated in cytoskeleton function. Modiﬁ-
cationof the actin expressionpattern indiabetic brainsmaybe related to
structural changes driven by the reorganization of actin-microﬁlaments
in the cell during the evolution of diabetes. Changes in neuronal activity
can bring about rapid alteration of the size and morphology of these
structures [41,42] which in turn may change the synaptic efﬁcacy; the
dynamics of actin are particularly important in this process [43].
Another proteomic analysis of postsynaptic density identiﬁed many
actin-regulatory proteins and an insulin receptor substrate protein that,
when associated, increases the dynamics of actin [44].
For the ﬁrst time, we report overexpression of myosin-IIB in
diabetic brain tissue. Although myosin-IIB lacks a calmodulin binding
site, the light chain of this molecular motor interacts with and is
regulated by a myosin light chain kinase that does have a calmodulin-
binding site. Thus, myosin-IIB may have been co-puriﬁed with other
calmodulin-binding molecules in our experiment.
Our analysis produced 61 peptides with m/z ratios ranging from
704.3800 to 2532.1070, in accordance with the predicted mass of
in silico-digested non-muscle myosin heavy chain IIB (Fig. 2A). The
myosin-IIB identiﬁed in this search (accession number 13928704) has
an estimated molecular mass of 229.79 kDa and an isoelectric point of
5.49 (Fig. 2B). A Mascot search of the NCBI protein database revealed
that these peptides covered 34% of the Rattus norvegicus myosin-IIB
sequence (Fig. 2C).
To evaluate the expressed protein concentration of myosin-IIB,
western blot analysis was performed using supernatant from rat brain
tissue.We observed an increase of about 59% in brain tissue of diabetic
rats relative to that of non-diabetic rats (pb0.05) (Fig. 3). The dif-
ferential expression of myosin-IIB protein in non-diabetic and diabetic
brains originally observed by afﬁnity chromatography, SDS-PAGE and
western blotting was validated by real time PCR of MYH10 mRNA
expression and by immunohistochemical analysis of the distribution
of myosin-IIB protein.
Real-time PCR (Fig. 4) revealed that theMYH10mRNA levelwas 1.4-
fold higher in diabetic brain tissue (pb0.001) than in non-diabetic, inFig. 5. Comparison of myosin-IIB distribution in non-diabetic and diabetic rat brains. In neuro
exhibits a higher expression for myosin-IIB than non-diabetic (A, D). It presented brown immagreement with the western blot. The ampliﬁcation efﬁciency was
tested using standard curves for Rattus norvegicus B2M (R2=0.9997)
andMYH10 (R2=0.996) generated by plotting the value of the CT cycle
vs. the log of plasmid concentration (from 104 to 106 copies). Linear
regression analysiswas used to determine the slope,which corresponds
to the ampliﬁcation efﬁciency. A slope value of about −3.2 with
R2≥0.99 suggested a reaction efﬁciency of 100% (Fig. 4B).
The distribution of myosin-IIB protein was also analyzed by
immunohistochemistry (Fig. 5). In the cerebral cortex, myosin-IIB
immunoreactivity was observed mainly in pyramidal neurons that are
known to be projecting neurons. The neuronal and glial cells of the
frontal and temporal cortex exhibited increased immunostaining for
myosin-IIB in diabetic rat brains. The distribution of myosin-IIB in other
regions of the brain was the same for non-diabetic and diabetic rats.
Our results are consistent with the previously reported distribution of
non-muscle myosin isoforms (myosin-IIA and myosin-IIB) in normal
rat brain [45]. Although the distribution of myosin-IIB is similar in
brains of diabetic and non-diabetic rats, the differential staining pattern
may be linked with myosin-IIB function.
Disturbances in insulin signaling appear to be the primary
impairment that affects cell growth and differentiation, cellular repair
mechanisms, energy metabolism, and glucose levels [46]. It has been
reported that IGF-I increases the level of myosin-IIB heavy chain
mRNA in skeletal muscle [47].
Extensive evidence has conﬁrmed that myosin-IIB plays a role in
the secretory processes of a variety of cells, including mast cells [48],
natural killer cells [49], hippocampal cells [50], sensory neurons [51],
chromafﬁn cells [52], beta cells [53], exocrine cells [54–56] and
oocytes [57]. Furthermore, this myosin is abundant in neuronal cell
bodies and neurites, where it is important for growth cone motility
and axon outgrowth [16,58].
Myosin-IIA was recently localized in mitochondria [59], which
may indicate that it plays a role during hyperglycemia. It is also
possible that the expression of myosin-IIB alters due to decreased
insulin levels resulting from streptozotocin-induced diabetes; if
myosin-IIB overexpression is speciﬁc to this model, then inhibition
should at least partly restore myosin levels in diabetes [60].
The identiﬁcation of calmodulin-binding proteins in the brain that
are expressed atdifferent levelsunder distinct conditionsmayshed light
on many important biochemical pathways and aid in the discovery of
novel calmodulin targets. Our study is the ﬁrst to describe the
expression of calmodulin-binding proteins in the non-diabetic andnal (arrow) and glial (arrowhead) cells of the frontal and temporal cortex, diabetic (B, E)
unostaining. Controls (C, F). Bar: 25 μm.
49L.K. Calábria et al. / Journal of the Neurological Sciences 303 (2011) 43–49diabetic brain tissue through a comparative proteomic study and to
examine the overexpression of non-muscle myosin heavy chain IIB in
diabetic rats. This report opens up new areas of study related to the
link between myosin-IIB levels in the brain and diabetes mellitus, a
metabolic disorder that is associated with a wide variety of long-term
complications.
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